================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

[X]    QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
       OF 1934

                For the quarterly period ended September 30, 2000

[ ]    TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

                 For the transition period from ______ to ______


                             LARK TECHNOLOGIES, INC.
        (Exact name of small business issuer as specified in its charter)


               DELAWARE                                     73-1461841
   (State or other jurisdiction of                        (IRS Employer
    Incorporation or organization)                      Identification No.)


                 9441 WEST SAM HOUSTON PARKWAY SOUTH, SUITE 103
                                HOUSTON, TX 77099
                    (Address of principal executive offices)


                                 (713) 779-3663
                           (Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.  Yes [X]    No [ ]

                APPLICABLE ONLY TO ISSUER INVOLVED IN BANKRUPTCY

                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court.   Yes [ ]     No[ ]


                      APPLICABLE ONLY TO CORPORATE ISSUERS

As of September 30, 2000, there were 3,512,673 shares of Common Stock, par value
$0.001 per share, outstanding.

Transitional Small Business Disclosure Format (Check one):   Yes [ ]    No [X]

================================================================================
<PAGE>
                             LARK TECHNOLOGIES, INC.

                              INDEX TO FORM 10-QSB
                    FOR THE QUARTER ENDED SEPTEMBER 30, 2000.

Part I  Financial Information (unaudited)
                                                                           PAGE

      Item 1. Financial Statements

              Balance Sheet ...............................................  1

              Statements of Income ........................................  2

              Statements of Cash Flows ....................................  3

              Notes to Financial Statements ...............................  4

      Item 2. Management's Discussion and Analysis
                of Financial Condition and Results of Operations...........  7

Part II  Other Information ................................................  9

      Item 1. Legal Proceedings ............................................ 9

      Item 2. Changes in Securities ........................................ 9

      Item 3. Defaults Upon Senior Securities............................... 9

      Item 4. Submission of Matters to a Vote of Security Holders........... 9

      Item 5. Other Information ............................................ 9

      Item 6. Exhibits and Reports on Form 8-K ............................. 9

Signatures ................................................................ 10

                                        i
<PAGE>
                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS

                             LARK TECHNOLOGIES, INC.
                                  BALANCE SHEET


                                                              September 30, 2000
                                                              ------------------
                                                                  (Unaudited)
ASSETS
Current assets:

      Cash and cash equivalents ...............................  $   650,496
      Accounts receivable, net ................................      953,652
      Due from related parties ................................        8,000
      Work-in-process .........................................       42,675
      Finished goods ..........................................      149,656
      Prepaid expenses ........................................       93,013
                                                                 -----------
Total current assets ..........................................    1,897,491

Property and equipment, net ...................................      970,695
Other assets, net .............................................       30,390
                                                                 -----------
Total assets ..................................................  $ 2,898,575
                                                                 ===========

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
      Accounts payable ........................................  $   337,287
      Notes payable ...........................................      387,412
      Capital lease obligations-current portion ...............       60,293
      Accrued expenses ........................................      105,487
      Customer deposits .......................................      669,401
      Deposits from related parties ...........................       86,889
                                                                 -----------
Total current liabilities .....................................    1,646,769

Note payable-long term portion ................................        2,444
Capital lease obligations-long term portion ...................       87,122
                                                                 -----------
Total liabilities: ............................................    1,736,335

Stockholders' equity
      Preferred stock, $0.001 par value:
           Authorized shares - 2,000,000
           None issued and outstanding
      Common stock, $0.001 par value:
           Authorized shares - 8,000,000
           Issued shares: 3,517,173 and outstanding
              shares: 3,512,673 ...............................        3,517
      Additional paid-in capital ..............................    2,667,291
      Treasury stock at cost ..................................       (4,946)
      Amounts due from shareholders ...........................      (15,045)
      Accumulated deficit .....................................   (1,488,577)
                                                                 -----------
Total stockholders' equity ....................................    1,162,240
                                                                 -----------
Total liabilities and stockholders' equity ....................  $ 2,898,575
                                                                 ===========

SEE ACCOMPANYING NOTES TO THE FINANCIAL STATEMENTS.

                                        1
<PAGE>
                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS

                             LARK TECHNOLOGIES, INC.
                              STATEMENTS OF INCOME

<TABLE>
<CAPTION>
                                           THREE MONTHS ENDED SEPTEMBER 30,      NINE MONTHS ENDED SEPTEMBER 30,
                                            ----------------------------         -----------------------------
                                                1999             2000                1999              2000
                                            -----------      -----------         -----------       -----------
                                                     (Unaudited)                           (Unaudited)
<S>                                             <C>              <C>                 <C>               <C>
Revenue:
   Laboratory services ..................   $ 1,468,824      $ 1,619,265         $ 3,712,762       $ 4,305,192


Costs and expenses:
   Costs of services ....................       795,172          920,433           2,240,057         2,623,120
   Sales, general and administrative ....       500,092          534,778           1,509,529         1,461,503
   Research and development .............             0                0                (395)                0
                                            -----------      -----------         -----------       -----------
Total costs and expenses ................     1,295,265        1,455,211           3,749,190         4,084,623
                                            -----------      -----------         -----------       -----------
Operating income (loss) .................       173,559          164,054             (36,428)          220,569


Other income and (expense):
   Interest expense .....................       (17,519)         (18,064)            (51,708)          (55,087)
   Interest income ......................           715            4,212               6,304             9,539
                                            -----------      -----------         -----------       -----------
Total other income (expense) ............       (16,804)         (13,852)            (45,404)          (45,548)
                                            -----------      -----------         -----------       -----------
Income (loss) before income taxes .......       156,756          150,202             (81,831)          175,021


Provision for income taxes ..............             0            7,876                   0             7,876
                                            -----------      -----------         -----------       -----------
Net income (loss) .......................   $   156,756      $   142,326         ($   81,831)      $   167,145
                                            ===========      ===========         ===========       ===========

Basic and diluted earnings (loss)
   per common share .....................          0.05             0.04         ($     0.02)      $      0.05
                                            ===========      ===========         ===========       ===========

Weighted average common
   shares outstanding: ..................     3,319,546        3,499,731           3,319,546         3,455,741
</TABLE>

SEE ACCOMPANYING NOTES TO THE FINANCIAL STATEMENTS.

                                        2
<PAGE>
                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS

                             LARK TECHNOLOGIES, INC.
                            STATEMENTS OF CASH FLOWS

                                                           NINE MONTHS ENDED
                                                             SEPTEMBER 30,
                                                        -----------------------
                                                           1999          2000
                                                        ---------     ---------
                                                               (Unaudited)

OPERATING ACTIVITIES

Net income (loss) ..................................    ($ 81,831)    $ 167,145
Adjustments to reconcile net income (loss)
  to net cash provided by (used in)
  operating activities
    Depreciation and amortization ..................      229,470       263,778
    Provision for bad debts ........................         --          17,000
    Changes in operating assets and liabilities:
       Accounts receivable .........................     (279,098)      (45,744)
       Inventory ...................................      (58,201)       37,397
       Prepaid expenses ............................       51,761        51,214
       Other Assets ................................        1,799           360
       Due from related parties ....................       13,326         1,064
       Accounts payable ............................     (109,164)     (275,249)
       Accrued expenses ............................       99,130       (57,259)
       Deposits ....................................      (83,632)      534,698
                                                        ---------     ---------
Net cash provided by (used in)
  operating activities .............................     (216,441)      694,405

INVESTING ACTIVITIES

Purchases of property and equipment ................      (96,549)     (167,654)
                                                        ---------     ---------
Net cash used in investing activities ..............      (96,549)     (167,654)

FINANCING ACTIVITIES

Proceeds from issuance of notes payable ............      480,567       106,500
Principal payments on notes payable ................     (213,399)     (250,013)
Principal payments on capital leases ...............     (170,187)     (157,784)
Proceeds from exercised stock options ..............         --         172,962
Proceeds from exercised warrants ...................         --          12,500
Redemption of warrants .............................         --         (31,250)
                                                        ---------     ---------
Net cash provided by (used in)
  financing activities .............................       96,981      (147,085)
                                                        ---------     ---------
Net increase (decrease) in cash and
  cash equivalents .................................     (216,009)      379,665
Cash and cash equivalents at beginning
  of period ........................................      465,506       270,830
                                                        ---------     ---------
Cash and cash equivalents at end of period .........      249,498     $ 650,496
                                                        =========     =========


SEE ACCOMPANYING NOTES TO THE FINANCIAL STATEMENTS.

                                        3
<PAGE>
                             LARK TECHNOLOGIES, INC.
                          NOTES TO FINANCIAL STATEMENTS
                                   (UNAUDITED)

1.    ORGANIZATION

      Lark Technologies, Inc., a Delaware corporation (the "Company"), was
formed on November 16, 1994, as a wholly-owned subsidiary of SuperCorp Inc.
("SuperCorp"), for the purpose of merging with Lark Sequencing Technologies,
Inc., a Delaware corporation ("Sequencing"), as outlined in a merger agreement
("Merger Agreement") entered into by SuperCorp and Sequencing on October 28,
1994. SuperCorp approved the Merger Agreement on September 5, 1995 and by the
stockholders of Sequencing on September 12, 1995. As a consequence of the
merger, all of the shares of common and preferred stock of Sequencing were
exchanged for 1,800,000 shares of Common Stock of the Company with a par value
of $0.001 per share and the 200,000 shares of Common Stock of the Company held
by SuperCorp were distributed to the shareholders of SuperCorp. The Company has
succeeded to all of the business previously undertaken by Sequencing. Lark
provides specialized laboratory services for DNA sequencing to biotechnology
researchers.

2.    ACCOUNTING POLICIES

BASIS OF PRESENTATION

      The accompanying unaudited interim financial statements have been prepared
pursuant to the rules and regulations of the Securities and Exchange Commission.
Certain information in footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted pursuant to these rules and regulations. The
accompanying unaudited interim financial statements reflect all adjustments
which the Company considers necessary for a fair presentation of the results of
operations for the interim periods covered and for the financial condition of
the Company at the date of the interim balance sheet. All such adjustments are
of a recurring nature. Results for the interim periods are not necessarily
indicative of results for the year.

      For financial reporting purposes, the merger of the Company and Sequencing
has been accounted for as a recapitalization of Sequencing, and the historical
financial statements of Sequencing prior to the merger became the financial
statements of the Company.

RECENTLY ISSUED ACCOUNTING STANDARDS

      In December 1999, the Securities and Exchange Commission (SEC) issued
Staff Accounting Bulletin 101, Revenue Recognition in Financial Statements ("SAB
101"), which the Company is required to adopt in the first quarter of 2000. In
March 2000, the SEC issued SAB 101A and temporarily delayed adoption. SAB 101
clarifies how existing revenue recognition rules should be applied. The Company
is currently evaluating its revenue recognition policies and the potential
effect of the adoption of SAB101.

RECLASSIFICATIONS

Certain amounts in prior years have been reclassified to conform to the 2000
presentation.

3.    INVENTORY

      Finished goods inventory consists of the direct and indirect costs to
produce quantitative polymerase chain reaction (QPCR) assays held for resale. At
September 30, 2000 finished goods inventory was $149,656.

      Work in process inventory includes the direct and indirect costs
associated with projects that had been started but not yet completed at
September 30, 2000. Direct costs include such items as the cost of labor,
reagents and supplies directly associated with each project. Indirect costs
include such items as general supplies, laboratory management, depreciation, and
costs to operate the lab. These costs are applied to each project on the basis
of direct

                                        4
<PAGE>
labor hours incurred for the project, up to the point of measurement, such as
the end of an accounting period. At September 30, 2000, work in process
inventory was $42,675.

4.    NOTES PAYABLE

      On December 31, 1999, the Company renewed its revolving line of credit and
extended the maturity to December 31, 2000. Under the terms of its revolving
line, the Company may borrow up to $600,000 at the bank's prime rate (9.5% at
September 30, 2000) plus 2%. The borrowing base of this line of credit is equal
to 80% of certain accounts receivable that are no more than 90 days old. On
September 30, 2000 the Company had $323,956 outstanding under this line. Under
the terms of the revolving line of credit agreement, the Company is required to
maintain certain financial ratios and a specific level of net worth. As of
September 30, 2000, the Company was in compliance with all required financial
ratios and specific net worth requirements.

      On March 13, 1998, the Company arranged an advised discretionary credit
line for the financing of equipment with the same bank used for the line of
credit described above. Under the terms of this discretionary credit, the
Company was able to borrow up to $600,000 secured by the equipment purchased
with the proceeds of the borrowings. This discretionary credit line provided for
the borrowings of up to 75% of the purchase price of equipment at the bank's
prime plus 1.5%. This credit line provided for repayment terms up to 36 months
and matured on May 31, 1999. On January 5, 1999, the Company borrowed $22,000
against this line of credit for the purchase of lab equipment. As of September
30, 2000, a balance of $9,778 remained on this loan.

      On March 31, 2000, the Company arranged a $75,000 term loan from the same
bank that extended the revolving credit facility. Under the terms of the loan,
the Company is to make substantially equal payments over a nine-month period
with the last payment on November 18, 2000. Interest is payable monthly at the
bank's prime rate plus 2%. On September 30, 2000, the Company owed $16,667 under
this note.

5.    EARNINGS PER SHARE

      The following table sets forth the weighted average shares outstanding for
the computation of basic and diluted earnings per share:

<TABLE>
<CAPTION>
                                                FOR THE THREE MONTHS ENDING      FOR THE NINE MONTHS ENDING
                                                        SEPTEMBER 30,                  SEPTEMBER 30,
                                                   1999              2000          1999              2000
                                                ---------         ---------     ---------         ---------
<S>                                             <C>               <C>           <C>               <C>
Weighted average common shares outstanding:     3,319,546         3,499,731     3,319,546         3,455,741
Dilutive securities - employee stock options:     139,463           169,729        50,632           223,724
                                                ---------         ---------     ---------         ---------
Weighted average common shares outstanding
  Assuming full dilution:                       3,459,009         3,669,460     3,370,178         3,679,465
                                                =========         =========     =========         =========
</TABLE>

      Options to purchase 268,322 shares of common stock were outstanding during
1999 but were not included in the computation of diluted earnings per share
because the effect would be antidilutive.

6.    COMMITMENTS AND CONTINGENCIES

STOCK OPTIONS AND WARRANTS

      During the quarter, options to purchase 23,335 shares of common stock were
exercised at various prices, ranging from $.72 to $2.00 per share.

PATENT LICENSE AGREEMENT

      Effective June 15, 1995, the Company entered into an exclusive patent
sub-license agreement with another biotech company. The agreement grants to the
Company an exclusive license to certain "Licensed Patent Rights" of this third
party and requires the Company to perform research and development efforts as
defined in the agreement. The Company is required to pay the third party a
royalty of 25% to 50% of all consideration the Company receives as a result of
sales of licensed products and licensed processes or a sub-license or assignment
of the Company's

                                       5
<PAGE>
rights under the agreement. If the Company does not meet the research and
development milestones as defined in the agreement, or is unable to successfully
commercialize the results of the research and development efforts, the agreement
will terminate. Otherwise, the agreement will terminate upon the dissolution of
the Company or the expiration of the "Licensed Patent Rights". The Company may
also terminate the agreement with 60 days written notice to the third party.

SPONSORED RESEARCH CONTRACT

      On October 6, 1998, the Company announced the restructuring of its
senescence technology development program. Sennes Drug Innovations, Inc., the
Company's licensor for the senescence technology, which originated with a third
party, recently appointed a new president. This appointment was allowed by the
settlement of various technology transfer issues between the third party and
Sennes. This new president will represent the Sennes technologies, including the
senescence gene technology licensed to the Company, to third parties. The
Company's license for senescence technologies remains intact.

      The senescence technology includes genes involved in regulating the four
senescence gene pathways. Senescence is the normal physiological process that
controls cellular immortality. Immortal cells are closely related to cancer and
can add insights into aging and abnormal development.

COMMITMENTS AND CONTINGENCIES

      The Company is involved in various legal proceedings that have arisen in
the ordinary course of business. In the opinion of management, based on
consultations with counsel and a review of the facts, the ultimate liability to
the Company will not have a material effect on the financial position of the
Company.

                                        6
<PAGE>
      ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
              RESULTS OF OPERATIONS

      The following discussion and analysis should be read in conjunction with
the Financial Statements and the accompanying Notes herein, and is qualified
entirely by the foregoing and by other more detailed financial information
appearing elsewhere.

GENERAL

      Lark Technologies, Inc. ("Lark" or "the Company") is a successor in
interest, through a merger effected in September 1995, to Lark Sequencing
Technologies, Inc., which was incorporated under the business corporation laws
of the State of Delaware on May 4, 1990.

      Lark is a leading molecular biology Contract Research Organization (CRO)
providing services to the pharmaceutical and biotechnology industries worldwide.
Lark's service portfolio consists of various DNA sequencing and molecular
biology services as follows:

o     AUTOMATED DNA SEQUENCING SERVICES. Lark applies automated sequencing
      techniques to generate high throughput DNA sequence and fast turnaround
      screening information, including genome sequencing, shotgun sequencing and
      shotgun library construction services.

o     GENETIC STABILITY TESTING SERVICES. Lark's genetic stability testing
      services are used to characterize Master Cell Banks, Manufacturers'
      Working Cell Banks and PostProduction Cell Samples from bacterial, yeast
      and cell cultures. Genetic stability testing is used to analyze a
      production strain's stability and demonstrate that the expression system
      has not undergone any mutations or rearrangements that would affect the
      integrity of the product. This service assists companies producing
      genetically manufactured products to optimize production yields, determine
      product purity, and support regulatory submissions. This service was
      introduced in late 1996.

o     QUANTITATIVE POLYMERASE CHAIN REACTION (PCR) SERVICES. Lark uses
      Quantitative PCR techniques to measure the distribution and expression of
      target DNA or RNA in a customer's sample from cultured cells,
      microorganisms, or tissues such as brain, lung, liver, and kidneys.

o     ARRAY SERVICES. Lark uses automated PCR techniques to produce molecular
      materials used in the construction of biochip arrays.

o     MOLECULAR BIOLOGY SERVICES. Lark offers a variety of molecular biology
      services including library screening, library prescreening, southern blot
      analysis, subcloning, plasmid preparation and PCR amplification. Lark
      consults with its customers to customize a broad range of molecular
      biology projects.

o     DIFFERENTIAL DISPLAY SERVICE. Lark uses differential display techniques
      for analyzing differences in gene expression caused by the introduction of
      various drug compounds, viruses or stimulatory factors. Differential
      display can be useful in identifying novel genes and gene functions. By
      understanding how and when a gene is expressed or repressed, targeted
      interventions can be developed to maximize results and minimize harmful
      side effects. This service is used to discover novel genes as well as to
      characterize pharmaceutical effects.

      In 1995 Lark undertook a senescence gene discovery program for its own
account. Although several genes were discovered in this program, lack of gene
functionality coupled with license issues caused Lark to reduce its funding for
this program. Lark continues to work towards license issue resolution and
eventual potential sublicense agreements.

                                        7
<PAGE>
RESULTS OF OPERATIONS

      GROSS REVENUES. Gross revenues increased 10% from $1,468,824 to $1,619,265
for the three-month periods ended September 30, 1999 and 2000, respectively.
Gross revenue increased 16% from $3,712,762 to $4,305,192 for the nine-month
periods ended September 30, 1999 and 2000 respectively. The increase in revenues
for the quarter and nine months was due to significant increases in all of the
segments of the Company's current business model.

      COSTS OF SERVICES. Costs of services consist primarily of labor and
laboratory supplies. Costs of services increased 16% from $795,172 to $920,433
for the three-month periods ended September 30, 1999 and 2000, respectively.
Costs of services increased 17% from $2,240,057 to $2,623,120 for the nine-month
periods ended September 30, 1999 and 2000, respectively. Part of the increase in
costs of services was due to the additional variable costs necessary to produce
the additional revenue for the quarter. Another part of the increase was the
addition of three new positions during third quarter of 2000 that did not exist
during the third quarter of 1999. These new positions were: a director of
quality assurance, a director of bioinformatics and an administrative support
person. Costs of services as a percentage of revenue were 54% and 57% for the
three-month periods ending September 30, 1999 and 2000, respectively and 60% and
61% for the nine-month periods ended September 30, 1999 and 2000, respectively.

      SALES, GENERAL AND ADMINISTRATIVE EXPENSES. Sales, general and
administrative expenses consist primarily of salaries and related costs,
depreciation, amortization, legal and professional costs, rent, travel, and
advertising. Sales, general and administrative expenses increased 7% from
$500,092 to $534,778 for the three-month periods ended September 30, 1999 and
2000, respectively. The increase was mainly due to recruitment costs of
approximately $72,000 incurred to hire a new sales representative in the western
sales region of the US and a new senior vice president of sales and marketing.
Sales, general and administrative expenses decreased 3% from $1,509,529 to
$1,461,503 for the nine-month period ended September 30, 1999 and 2000,
respectively. These decreases were due, in part, to the departure of the
Company's previous president in November 1999. Sales, general and administrative
expenses as a percentage of revenue were 34% and 33% for the three-month and 41%
and 34% for the nine-month periods ended September 30, 1999 and 2000,
respectively.

      VARIABILITY OF FUTURE OPERATING RESULTS In 1998, the Company adopted a new
business model that broadened its services and expanded its customer base. The
favorable results reported for the third quarter of 1999 reflected the first
profitable quarter for this business model. That success was continued in the
fourth quarter of 1999 and was interrupted, in the first quarter of 2000, only
by the extra expenses and disruption incurred to relocate the Company to its new
headquarters and lab facility in Houston during January of 2000. The profitable
trend continued into the third quarter of 2000 although earnings were somewhat
lower due to the recruiting expenses explained in the sales, general and
administrative section above. As the Company continues to grow, additional
expenses will be required to add the personnel and equipment necessary. The
Company continues to seek large contracts and diversify its customer base.

      LIQUIDITY AND CAPITAL RESOURCES. Operating cash flow was ($216,441) and
$694,405 for the nine-month periods ended September 30, 1999 and 2000,
respectively. The positive operating cash flow for the quarter ending September
30, 2000 occurred primarily as a result of the net income reported for the
period and net increase in customer deposits. During this quarter, the Company
managed to reduce trade payables by $100,963 with funds provided from
collections of accounts receivable and other sources.

      On December 31, 1999, the Company renewed its revolving loan facility
through December 31, 2000, and may now borrow up to $600,000 under the terms of
the new credit line. On March 31, 2000, the Company borrowed $75,000 under a new
term loan payable in monthly installments and maturing November 18, 2000. See
note 4 to financial statements for further details of the Company's borrowing
facilities.

      During the third quarter of 2000, incentive stock options to purchase
23,335 shares of common stock were exercised at various prices, ranging from
$.72 to $2.00.

                                        8
<PAGE>
      MATERIAL COMMITMENTS. The Company currently has no outstanding material
commitments.


                          PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

        The Company is involved in various legal proceedings that have arisen in
        the ordinary course of business. In the opinion of management, based on
        consultations with counsel and a review of the facts, the ultimate
        liability to the Company will not have a material effect on the
        financial position of the Company.

ITEM 2. CHANGES IN SECURITIES

        Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

        Not applicable.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

        Not applicable

ITEM 5. OTHER INFORMATION

        Not applicable.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

        No reports on Form 8-K were filed during the quarter ending September
        30, 2000.

INDEX OF EXHIBITS

    2.1(1)    The Agreement of Merger of November 18, 1994, between Lark
              Technologies,  Inc. and Lark Sequencing Technologies, Inc.
              providing for the merger of Lark Sequencing Technologies, Inc.
              into the Company.

    3.1(1)    Bylaws of Lark Technologies, Inc., as amended.

    3.2(1)    The Certificate of Incorporation of Lark Technologies, Inc.,
              as amended.

    4.1(3)    Lark Technologies, Inc. 2000 Stock Option Plan adopted by the
              Company.

  10.13(2)    Agreement entered into by and between the Company and
              Genomyx Corporation.

  10.14(2)    The portion of the Minutes of the Executive Session of the Meeting
              of the Board of Directors of the Company held December 8, 1995,
              establishing and defining the bonus plan for 1996 under which the
              chief executive officer, chief financial officer, and other
              employees may receive cash bonuses as part of their compensation.

(1) Incorporated by reference from the Company's Registration Statement on Form
S-4 dated August 14, 1995, Commission File No. 33-90424. The exhibit numbering
system used in Form S-4 differed from that used in this Form 10-QSB (8a, 2d, 2c,
6b, 6c, 6d-1, and 6f, respectively).

(2) Incorporated by reference from the Company's Form 10-QSB for the quarterly
period ended March 31, 1996.

(3) Incorporated by reference from the Company's Registration Statement on Form
S-8 dated September 21, 2000, Commission File No. 333-46280.

                                        9
<PAGE>
                                   SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                       Lark Technologies, Inc.
                                            (Registrant)



DATE NOVEMBER 13, 2000                 /s/ DOUGLAS B. WHEELER             .
                                           Douglas B. Wheeler
                                           President and Chief Operating Officer

                                       10